שווי כולל של החברה: Genelux (GNLX)

This price chart for Genelux Corporation (GNLX) illustrates the business valuation, which currently stands at 77.87. Genelux Corporation (GNLX) leads the development of viral systems for combating tumors, leveraging exclusive patents to shield itself from competitors. A calibrated low-temperature biomaterial transport system ensures a steady stream of revenue. However, success depends on high-risk testing, where any research failures could wipe out the invested capital.

Fundamental asset selection requires an analysis of the enterprise value, which combines market capitalization and net debt to determine the actual cost of acquiring a company. In the case of Genelux Corporation (GNLX), this calculation accounts for high R&D costs and operating losses, allowing for an assessment of how the platform's current risks and clinical trial expectations are reflected in the EV trend.